After eight daunting months of battling COVID-19, there may be some light at the end of the tunnel as two potential vaccine candidates recently announced promising test results. 

Vaccines from Pfizer and Moderna are similar in that they both use emerging technology called messenger ribonucleic acid (mRNA) to reach nearly 95 percent efficacy. Typically, scientists create vaccines by using live or inactivated virus cells, which puts the actual disease into a person’s body. However, with mRNA technology, Pfizer and Moderna were able to avoid that. MRNA carries coded instructions that tell cells what defenses are necessary by appearing as a threat. 

Of Course, There's a Catch

The use of the molecule is groundbreaking for a number of reasons. One is the speed at which the vaccines were developed. The other is that the use of mRNA means the vaccines contain no infectious COVID-19 properties that could get patients sick. 

However, there is a drawback to the vaccines: they have to be stored in brutally cold temperatures.

Under normal circumstances, vaccines can survive when stored at around 40 degrees Fahrenheit, but for Moderna, the vials must be stored at -4 degrees.

For Pfizer's vaccine, the threshold for keeping an effective dose is even steeper at a staggering -94 degrees. The icy temperatures are necessary to keep the mRNA molecule intact, otherwise it “begins to fall apart and twist around in ways so that it doesn’t become effective,” a representative for the pharmaceutical giant told Cheddar.

Vaccine Storage & Distribution Roadblock

With the need for cold storage comes the obstacle of how to pull off widespread distribution. Most hospitals in the U.S. do not house facilities that meet the requirements to store either the Moderna or Pfizer vaccines for extended periods. Both vaccines are able to survive in typical storing temperatures of 35 to 46 degrees, but their shelf lives are limited that way.

For Pfizer, the vaccine would no longer be effective after five days in normal storage temperatures. Moderna, meanwhile, shows more promise when it comes to effective distribution as it’s vaccines appear to remain effective for a month while stored 35 degrees.

Pfizer has come up with a plan to ship its vaccine in boxes filled with dry ice. The vials will remain protected for up to 15 days -- but the container can only be opened up to two times per day. 

This could be a logistical nightmare for parts of the world that don't have sufficient equipment - or enough dry ice - to keep the vaccines. Even in rural America, many hospitals don't have freezers that can keep doses cold enough, particularly for the Pfizer vaccine.  

Getting Vaccinated

So what does this mean for you? Once the FDA approves emergency use authorization of either one or both of the vaccines, it looks like they will likely be distributed first among populations that need it the most: frontline healthcare workers, the elderly, and those suffering from underlying health conditions. 

Like several existing vaccinations for other conditions, both Pfizer and Moderna require two rounds of treatment in order for the body to build up complete immunity. For those receiving the Pfizer vaccine, patients will need to return for a second dose after three weeks and for those getting the Moderna vaccine, they'll have to go back for round two after four weeks. 

Video produced by Ali Larkin. Article written by Lawrence Banton.

Share:
More In Science
Chinese Lab Successfully Clones Two Monkeys
Dina Fine Maron, editor of Health & Science Medicine at Scientific American, discusses the news that Chinese scientists recently cloned two monkeys, raising questions about the practice.
Closing Bell: January 25, 2018
Harvard Business Review recently launched a brand new podcast. The six-episode "Women at Work" podcast explores women's place in the workplace. Grammy Awards are returning to New York City. Starbucks and Intel announce earnings. Actor Jake Johnson is teaming up with Natural Light for a new Super Bowl campaign. President Trump wraps the first day of a summit with world leaders in Davos. Reports reveal CBS and Viacom are talking about a merger. Robbinhood will let you buy and sell crypto without any transaction fees.
Trump's Impact on Science in the U.S.
Tanya Lewis, assistant editor at Scientific American, discusses the new tax the Trump administration recently placed on imported solar panels. She weighs in on what the decision means for the U.S. economy and for the consumer.
Closing Bell: January 24, 2018
Meryl Streep joins the cast of Big Little Lies." The White House announces it will roll out immigration Framework. Cheddar speaks with Danica Patrick about how she is readying for this race and life after Nascar. President Trump announces new tariffs on imported solar panels and washing machines. Burger King releases a net neutrality commercial. Hewlett Packard's CEO announcers her new venture.
Opening Bell: January 24, 2018
The European Union fines Qualcomm for allegedly violating antitrust laws. Starbucks and Disney announce pay raises and better employee benefits thanks to savings from the new tax reform bill. We talk to the directors behind the newest Netflix series, "Dirty Money," premiering this Friday, January 26th. And Brett Holts, VP of Nike Running Footwear, introduces Nike's newest sneaker, the Epic React Flyknit.
Inside Nike's Newest Innovation
Brett Holts, Vice President of Nike Running Footwear, introduces Nike's newest sneaker, the Epic React Flyknit. The new shoe features a brand new foam compound.
Load More